[Case Study] Keisuke Kagami and Mitsuru Sugawara “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis” (AMR Alliance Japan, March 7, 2022)
date : 3/7/2022
Tags: AMR
![[Case Study] Keisuke Kagami and Mitsuru Sugawara “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis” (AMR Alliance Japan, March 7, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-case06-top_ENG.jpg)
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital) and Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) reports a case titled “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis.”
This is the second of two case studies from AMR Alliance Japan on the usefulness of TDM for antimicrobial stewardship.
Case study 06
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis.”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
Case study 05
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
![[AMR Case Study 06] Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis](/assets/img/katsudo/icon_pdf_l.png){kind=icon}
Top Research & Recommendations Posts
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Policy Recommendations] Mental Health Project: Recommendations on Three Issues in the Area of Mental Health (July 4, 2025)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Policy Recommendations] Reshaping Japan’s Immunization Policy for Life Course Coverage and Vaccine Equity: Challenges and Prospects for an Era of Prevention and Health Promotion (April 25, 2025)
- [Policy Recommendations] Recommendations on Strategic Investments in Policies for Brain Health to Revitalize Japan: Hopes for the New Administration (December 1, 2025)
- [Announcement] HGPI Endorses the “Belém Health Action Plan” (November 14, 2025)
- [Announcement] HGPI Joins Global Green and Healthy Hospitals (August 1, 2023)
- [Research Report] AMR Policy Update #2: WHO’s First Report on Fungal Infection—Bridging the Gap Between Clinical Practice and R&D
Featured Posts
-
2025-12-09
[Event Report] Special Seminar “Rising to New Challenges in Health Sciences for Future Society: Novel Developments in the Field of Epilepsy in Japan and Globally” Belgium Pavilion Special Seminar, World Expo 2025 Osaka, Kansai (September 18, 2025)
![[Event Report] Special Seminar “Rising to New Challenges in Health Sciences for Future Society: Novel Developments in the Field of Epilepsy in Japan and Globally” Belgium Pavilion Special Seminar, World Expo 2025 Osaka, Kansai (September 18, 2025)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20250805_mental-health-expo-eyechatch.png)
-
2025-12-11
[Event Report] Core Components of Universal Health Coverage (UHC): Achieving “Healthcare Without Financial Hardship” in Asia-Pacific and Japan (December 5, 2025)
![[Event Report] Core Components of Universal Health Coverage (UHC): Achieving “Healthcare Without Financial Hardship” in Asia-Pacific and Japan (December 5, 2025)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20251210_Core-Components-of-Universal-Health-CoverageUHC-top.jpg)
-
2025-12-12
[Registration Open] Meaningful Involvement Promotion Project Urgent Symposium “The New Takaichi Administration and Central Social Insurance Medical Council Reform – Ensuring Patients’ Voices are Heard” (January 22, 2026)
![[Registration Open] Meaningful Involvement Promotion Project Urgent Symposium “The New Takaichi Administration and Central Social Insurance Medical Council Reform – Ensuring Patients’ Voices are Heard” (January 22, 2026)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20251208_urgent-symposium-1.png)
-
2025-12-12
[Registration Open] (Webinar) The 140th HGPI Seminar “Early Detection to Reduce COPD Disease Burden: Connecting Clinical Frontiers with Health Policy” (January 27, 2026)
![[Registration Open] (Webinar) The 140th HGPI Seminar “Early Detection to Reduce COPD Disease Burden: Connecting Clinical Frontiers with Health Policy” (January 27, 2026)](https://hgpi.org/en/wp-content/uploads/sites/2/hs140-top.png)
-
2025-12-16
[Discussion Points] Policy Dialogue “Considering Comprehensive Genomic Profiling from the Perspective of Patient Access: Utilizing the Medical Service Fee Reimbursement System and the Mixed Medical Services Program to Meet the Needs of Today” (November 28, 2025)
![[Discussion Points] Policy Dialogue “Considering Comprehensive Genomic Profiling from the Perspective of Patient Access: Utilizing the Medical Service Fee Reimbursement System and the Mixed Medical Services Program to Meet the Needs of Today” (November 28, 2025)](https://hgpi.org/en/wp-content/uploads/sites/2/eyecatch_Policy-Dialogue_Discussion-Points_20251128.jpg)
